Intermediate-size Patient Population Expanded Access Protocol
NCT07088159 · Status: AVAILABLE · Type: EXPANDED_ACCESS
Last updated 2026-03-24
Summary
The purpose of this Expanded Access Program is to provide SPG302 to ALS patients who are not eligible to enroll in an ALS clinical trial. This Expanded Access Program will assess safety and tolerability, and clinical efficacy of SPG302.
Conditions
- ALS (Amyotrophic Lateral Sclerosis)
Interventions
- DRUG
-
SPG302
300 mg SPG302 will taken by mouth once daily.
Sponsors & Collaborators
-
Spinogenix
lead INDUSTRY
Eligibility
- Min Age
- 18 Years
- Max Age
- 80 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
Countries
- United States
Study Locations
More Related Trials
-
A Study to Evaluate the Efficacy and Safety of Different Doses of CB03-154 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT07082192 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2/PHASE3
-
Clinical Trial of SB-509 in Subjects With Amyotrophic Lateral Sclerosis (ALS)
NCT00748501 ·Status: COMPLETED ·Phase: PHASE2
-
Home Monitoring of Adult Patients With SMA: a Pilot Multicenter Validation Study
NCT05839145 ·Status: NOT_YET_RECRUITING ·Phase: NA
-
EAP of Apitegromab for Patients With Spinal Muscular Atrophy
NCT06877689 ·Status: NO_LONGER_AVAILABLE
-
Expanded Access Protocol of BHV-0223 for Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT03537807 ·Status: NO_LONGER_AVAILABLE
-
Monitoring to the Evolution of Motor Function in SMA Type II Adults Patients Treated With SPINRAZA®
NCT04159987 ·Status: ACTIVE_NOT_RECRUITING ·Phase: NA
-
Intermediate-Sized Expanded Access Study
NCT05597436 ·Status: NO_LONGER_AVAILABLE
-
A Trial of Tocilizumab in ALS Subjects
NCT02469896 ·Status: COMPLETED ·Phase: PHASE2
-
Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS)
NCT06100276 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2
-
An Intermediate Size Expanded Access Protocol of AMX0035 for ALS
NCT05286372 ·Status: APPROVED_FOR_MARKETING
-
Two Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01 and CNMAu8.EAP02 for ALS
NCT05281484 ·Status: NO_LONGER_AVAILABLE
-
Clinical Trial of Ezogabine (Retigabine) in ALS Subjects
NCT02450552 ·Status: COMPLETED ·Phase: PHASE2
-
Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients with Spinal Muscular Atrophy Type 1
NCT05614531 ·Status: ENROLLING_BY_INVITATION ·Phase: PHASE1/PHASE2
-
Expanded Access Program for Tofersen in Participants With Superoxide Dismutase 1-Amyotropic Lateral Sclerosis
NCT04972487 ·Status: APPROVED_FOR_MARKETING
-
A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS)
NCT06441682 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Clinical Trial to Assess the Safety and Efficacy of EXG001-307 in Patients With Spinal Muscular Atrophy
NCT06888661 ·Status: ENROLLING_BY_INVITATION ·Phase: EARLY_PHASE1
-
Safety and Biomarker Study of EPI-589 in Participants With Amyotrophic Lateral Sclerosis (ALS)
NCT02460679 ·Status: COMPLETED ·Phase: PHASE2
-
Phase 3 Extension Study of Dexpramipexole in ALS
NCT01622088 ·Status: TERMINATED ·Phase: PHASE3
-
Dose Escalation and Safety Study of Human Spinal Cord Derived Neural Stem Cell Transplantation for the Treatment of Amyotrophic Lateral Sclerosis
NCT01730716 ·Status: UNKNOWN ·Phase: PHASE2
-
MRG-001 in Patients With Amyotrophic Lateral Sclerosis
NCT06315608 ·Status: NOT_YET_RECRUITING ·Phase: PHASE2
-
Multiple Doses of AT-1501-A201 in Adults With ALS
NCT04322149 ·Status: COMPLETED ·Phase: PHASE2
-
Humanitarian Device Exemption Post-Approval Study of NeuRx Diaphragm Pacing System for Amyotrophic Lateral Sclerosis
NCT01605006 ·Status: COMPLETED ·Phase: NA
-
Intrathecal Autologous Adipose-derived Mesenchymal Stromal Cells for Amyotrophic Lateral Sclerosis (ALS)
NCT03268603 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE2
-
Patients With ALS and Other Motor Disorders Will be Treated With Mesenchymal Cell Exosome Solution
NCT07105371 ·Status: COMPLETED ·Phase: PHASE1
-
Evaluation of Safety and Efficacy of Gene Therapy Drug in the Treatment of Spinal Muscular Atrophy (SMA) Type 2 Patients
NCT05901987 ·Status: ACTIVE_NOT_RECRUITING ·Phase: PHASE1/PHASE2